BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 10854129)

  • 1. O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials.
    Keir ST; Dolan ME; Pegg AE; Lawless A; Moschel RC; Bigner DD; Friedman HS
    Cancer Chemother Pharmacol; 2000; 45(6):437-40. PubMed ID: 10854129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.
    Friedman HS; Dolan ME; Moschel RC; Pegg AE; Felker GM; Rich J; Bigner DD; Schold SC
    J Natl Cancer Inst; 1992 Dec; 84(24):1926-31. PubMed ID: 1334154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
    Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
    Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-Methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2'-deoxyguanosine.
    Kokkinakis DM; Ahmed MM; Chendil D; Moschel RC; Pegg AE
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3801-7. PubMed ID: 14506174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. O6-methylguanine-DNA methyltransferase (MGMT) transfectants of a 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-sensitive colon cancer cell line selectively repopulate heterogenous MGMT+/MGMT- xenografts after BCNU and O6-benzylguanine plus BCNU.
    Phillips WP; Willson JK; Markowitz SD; Zborowska E; Zaidi NH; Liu L; Gordon NH; Gerson SL
    Cancer Res; 1997 Nov; 57(21):4817-23. PubMed ID: 9354444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Felker GM; Friedman HS; Dolan ME; Moschel RC; Schold C
    Cancer Chemother Pharmacol; 1993; 32(6):471-6. PubMed ID: 8258196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. O6-benzylguanine-mediated enhancement of chemotherapy.
    Friedman HS; Keir S; Pegg AE; Houghton PJ; Colvin OM; Moschel RC; Bigner DD; Dolan ME
    Mol Cancer Ther; 2002 Sep; 1(11):943-8. PubMed ID: 12481416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of BCNU antitumor efficacy by 9-substituted O6-benzylguanines. Effect of metabolism.
    Kokkinakis DM; Moschel RC; Pegg AE; Schold SC
    Cancer Chemother Pharmacol; 2000; 45(1):69-77. PubMed ID: 10647505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.
    Koç ON; Reese JS; Davis BM; Liu L; Majczenko KJ; Gerson SL
    Hum Gene Ther; 1999 Apr; 10(6):1021-30. PubMed ID: 10223735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
    Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J
    Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of BCNU anticancer activity by O6-benzylguanine: a study in vitro and in vivo.
    Wan Y; Wu D; Gao H; Lu H
    J Environ Pathol Toxicol Oncol; 2000; 19(1-2):69-75. PubMed ID: 10905510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea.
    Kreklau EL; Pollok KE; Bailey BJ; Liu N; Hartwell JR; Williams DA; Erickson LC
    Mol Cancer Ther; 2003 Dec; 2(12):1321-9. PubMed ID: 14707273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU).
    Dolan ME; Pegg AE; Moschel RC; Grindey GB
    Biochem Pharmacol; 1993 Jul; 46(2):285-90. PubMed ID: 8347150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-neoplastic activity of sequenced administration of O6-benzylguanine, streptozotocin, and 1,3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo.
    Marathi UK; Dolan ME; Erickson LC
    Biochem Pharmacol; 1994 Nov; 48(11):2127-34. PubMed ID: 7802703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended depletion of O6-methylguanine-DNA methyltransferase activity following O6-benzyl-2'-deoxyguanosine or O6-benzylguanine combined with streptozotocin treatment enhances 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity.
    Marathi UK; Dolan ME; Erickson LC
    Cancer Res; 1994 Aug; 54(16):4371-5. PubMed ID: 8044784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of human brain tumor xenografts with O6-benzyl-2'-deoxyguanosine and BCNU.
    Schold SC; Kokkinakis DM; Rudy JL; Moschel RC; Pegg AE
    Cancer Res; 1996 May; 56(9):2076-81. PubMed ID: 8616853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation.
    Mitchell RB; Moschel RC; Dolan ME
    Cancer Res; 1992 Mar; 52(5):1171-5. PubMed ID: 1737376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Davis BM; Reese JS; Koç ON; Lee K; Schupp JE; Gerson SL
    Cancer Res; 1997 Nov; 57(22):5093-9. PubMed ID: 9371508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.
    Wedge SR; Porteous JK; Newlands ES
    Br J Cancer; 1996 Oct; 74(7):1030-6. PubMed ID: 8855970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine.
    Loktionova NA; Xu-Welliver M; Crone TM; Kanugula S; Pegg AE
    Biochem Pharmacol; 1999 Jul; 58(2):237-44. PubMed ID: 10423163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.